Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Head & Neck 3Genitourinary 2Thoracic 1Plasma cell 1

Conditions

Prostatic Neoplasms 2Erectile Dysfunction 2Urinary Incontinence 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Tadalafil × Genitourinary × Clear all
NCT07576335 2026-05-08

ROBOPREP

Surgical Outcomes Research Centre (SOuRCe)

Phase 2 Not yet recruiting
64 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Urinary Incontinence

NCT05558007 2024-10-22

Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients

Biozeus Biopharmaceutical S.A.

Phase 2 Recruiting
72 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡